Abrogation of α-synuclein -mediated dopaminergic neurodegeneration in LRRK2-deficient rats

Proceedings of the National Academy of Sciences of the United States of America

Volumn 111, Issue 25, 2014, Pages 9289-9294

  Daher, João P L ^a   Volpicelli Daley, Laura A ^a   Blackburn, Jonathan P ^a   Moehle, Mark S ^a   West, Andrew B ^a  

^a UNIVERSITY OF ALABAMA AT BIRMINGHAM   (United States)

Author keywords

CD68; NACP; PARK8; Rat knockout; SNCA

Indexed keywords

ALPHA SYNUCLEIN; INDUCIBLE NITRIC OXIDE SYNTHASE; LEUCINE RICH REPEAT KINASE 2; LIPOPOLYSACCHARIDE;

ADENO ASSOCIATED VIRUS; ANIMAL EXPERIMENT; ARTICLE; BONE MARROW CELL; CELL LOSS; CONTROLLED STUDY; DOPAMINERGIC NERVE CELL; GENE MUTATION; GENE OVEREXPRESSION; HUMAN; KNOCKOUT RAT; NERVE DEGENERATION; NONHUMAN; PHENOTYPE; PRIORITY JOURNAL; PROTEIN EXPRESSION; RAT; SUBSTANTIA NIGRA;

CD68; NACP; PARK8; RAT KNOCKOUT; SNCA;

ALPHA-SYNUCLEIN; ANIMALS; HUMANS; LIPOPOLYSACCHARIDES; MYELOID CELLS; NEURODEGENERATIVE DISEASES; NITRIC OXIDE SYNTHASE TYPE II; PROTEIN-SERINE-THREONINE KINASES; RATS; RATS, TRANSGENIC; SUBSTANTIA NIGRA;

EID: 84903435402     PISSN: 00278424     EISSN: 10916490     Source Type: Journal    
DOI: 10.1073/pnas.1403215111     Document Type: Article

References (23)

1. Hulihan MM, et al. (2008) LRRK2 Gly2019Ser penetrance in Arab-Berber patients from Tunisia: A case-control genetic study. Lancet Neurol 7(7):591-594.
2. Ozelius LJ, et al. (2006) LRRK2 G2019S as a cause of Parkinson's disease in Ashkenazi Jews. N Engl J Med 354(4):424-425. (Pubitemid 43145083)
3. International Parkinson's Disease Genomics Consortium (IPDGC); Wellcome Trust Case Control Consortium 2 (WTCCC2) (2011) A two-stage meta-analysis identifies several new loci for Parkinson's disease. PLoS Genet 7(6):e1002142.
4. Nalls MA, et al.; International Parkinson Disease Genomics Consortium (2011) Imputation of sequence variants for identification of genetic risks for Parkinson's disease: A meta-analysis of genome-wide association studies. Lancet 377(9766):641-649.
5. Danoy P, et al.; Australo-Anglo-American Spondyloarthritis Consortium; Spondyloarthritis Research Consortium of Canada (2010) Association of variants at 1q32 and STAT3 with ankylosing spondylitis suggests genetic overlap with Crohn's disease. PLoS Genet 6(12):e1001195.
6. Zhang FR, et al. (2009) Genomewide association study of leprosy. N Engl J Med 361(27):2609-2618.
7. Lin X, et al. (2009) Leucine-rich repeat kinase 2 regulates the progression of neuropathology induced by Parkinson's-disease-related mutant alpha-synuclein. Neuron 64(6):807-827.
8. Daher JP, et al. (2012) Neurodegenerative phenotypes in an A53T α-synuclein transgenic mouse model are independent of LRRK2. Hum Mol Genet 21(11):2420-2431.
9. Herzig MC, et al. (2012) High LRRK2 levels fail to induce or exacerbate neuronal alpha-synucleinopathy in mouse brain. PLoS ONE 7(5):e36581.
10. Moehle MS, et al. (2012) LRRK2 inhibition attenuates microglial inflammatory responses. J Neurosci 32(5):1602-1611.
11. Thévenet J, Pescini Gobert R, Hooft van Huijsduijnen R, Wiessner C, Sagot YJ (2011) Regulation of LRRK2 expression points to a functional role in human monocyte maturation. PLoS ONE 6(6):e21519.
12. Kirik D, et al. (2002) Parkinson-like neurodegeneration induced by targeted overexpression of alpha-synuclein in the nigrostriatal system. J Neurosci 22(7):2780-2791. (Pubitemid 37465827)
13. Castaño A, Herrera AJ, Cano J, Machado A (1998) Lipopolysaccharide intranigral injection induces inflammatory reaction and damage in nigrostriatal dopaminergic system. J Neurochem 70(4):1584- 1592.
14. Harms AS, et al. (2013) MHCII is required for α-synuclein-induced activation of microglia, CD4 T cell proliferation, and dopaminergic neurodegeneration. J Neurosci 33(23):9592-9600.
15. Ransohoff RM, Cardona AE (2010) The myeloid cells of the central nervous system parenchyma. Nature 468(7321):253-262.
16. Fellner L, et al. (2013) Toll-like receptor 4 is required for α-synuclein dependent activation of microglia and astroglia. Glia 61(3):349-360.
17. Sanchez-Guajardo V, Febbraro F, Kirik D, Romero-Ramos M (2010) Microglia acquire distinct activation profiles depending on the degree of alpha-synuclein neuropathology in a rAAV based model of Parkinson's disease. PLoS ONE 5(1):e8784.
18. Davies P, et al. (2013) Comprehensive characterization and optimization of anti-LRRK2 (leucine-rich repeat kinase 2) monoclonal antibodies. Biochem J 453(1):101-113.
19. West AB, et al. (2014) Differential LRRK2 expression in the cortex, striatum, and substantia nigra in transgenic and nontransgenic rodents. J Comp Neurol, 10.1002/cne.23583.
20. Luk KC, et al. (2012) Pathological α-synuclein transmission initiates Parkinson-like neurodegeneration in nontransgenic mice. Science 338(6109):949-953.
21. Cookson MR (2010) The role of leucine-rich repeat kinase 2 (LRRK2) in Parkinson's disease. Nat Rev Neurosci 11(12):791-797.
22. Giasson BI, et al. (2000) A panel of epitope-specific antibodies detects protein domains distributed throughout human alpha-synuclein in Lewy bodies of Parkinson's disease. J Neurosci Res 59(4):528-533. (Pubitemid 30090580)
23. Waxman EA, Duda JE, Giasson BI (2008) Characterization of antibodies that selectively detect alpha-synuclein in pathological inclusions. Acta Neuropathol 116(1):37-46. Neurological Disorders and Stroke